To detect gene mutation sites, we combined RPA with the CRISPR/Cas12a-based biosensors to diagnose chromosome-negative myeloproliferative neoplasms (MPNs) in Philadelphia by detecting JAK2 V617F mutations using LFA [88]. Here, JAK2 is linked to myeloproliferative disorder.